Evaluation of four commercial severe acute respiratory coronavirus 2 antibody tests

INTRODUCTION: Numerous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests exists commercially; however, their performance using clinical samples is limited. Although insufficient to detect SARS-CoV-2 in the early phase of infection, antibody assays can be of great use for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashizawa, Nobuyuki, Takazono, Takahiro, Ohyama, Kaname, Nagasaki, Yoji, Okamoto, Masaki, Hirayama, Tatsuro, Takahashi, Kensuke, Yamanashi, Hirotomo, Tashiro, Masato, Hosogaya, Naoki, Tanaka, Takeshi, Yamamoto, Kazuko, Fukuda, Yuichi, Imamura, Yoshifumi, Kawanami, Toshinori, Miyazaki, Taiga, Sawai, Toyomitsu, Fukushima, Kiyoyasu, Yatera, Kazuhiro, Yanagihara, Katsunori, Izumikawa, Koichi, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959261/
https://www.ncbi.nlm.nih.gov/pubmed/33781691
http://dx.doi.org/10.1016/j.jiac.2021.03.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959261/
https://www.ncbi.nlm.nih.gov/pubmed/33781691
http://dx.doi.org/10.1016/j.jiac.2021.03.008

Ejemplares similares